Research programme: sublingual allergy immunotherapies - ALK-AbelloAlternative Names: Cat allergy vaccine; Recombinant allergy vaccine tablets; Tablet-based allergy vaccines - ALK-Abello
Latest Information Update: 08 Jul 2011
At a glance
- Originator ALK-Abello
- Class Allergens; Allergy immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Hypersensitivity
Most Recent Events
- 06 Jul 2011 Early research in Hypersensitivity in Denmark (Sublingual)
- 31 Jan 2007 Preclinical development is ongoing
- 30 Nov 2005 The programme is still in active development